Get the Stockscreener App
15.21
8.65%
-1.44
After Hours:
15.19
-0.02
-0.13%
Tourmaline Bio Inc stock is traded at $15.21, with a volume of 279.21K.
It is down -8.65% in the last 24 hours and up +16.20% over the past month.
See More
Previous Close:
$16.65
Open:
$16.22
24h Volume:
279.21K
Relative Volume:
0.98
Market Cap:
$452.32M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
26.29
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
-13.63%
1M Performance:
+16.20%
6M Performance:
-40.84%
1Y Performance:
-33.58%
1-Day Range:
$14.87
$16.22
1-Week Range:
$14.87
$17.80
52-Week Range:
$11.87
$29.79
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
15.21 | 452.32M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Swiss National Bank Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Leading Factor Driving the Thyroid Eye Disease (TED) Market in 2025: Thyroid Disorders And Their Influence ... - WhaTech
ProfittoPath - TradingView
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Sold by AlphaQuest LLC - Defense World
Tourmaline Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Tourmaline Bio (NASDAQ:TRML) Stock Price Expected to Rise, Wedbush Analyst Says - Defense World
HC Wainwright Raises Tourmaline Bio (NASDAQ:TRML) Price Target to $50.00 - Defense World
H.C. Wainwright raises Tourmaline Bio stock target to $50 By Investing.com - Investing.com Canada
Tourmaline Bio price target raised to $43 from $42 at Wedbush - TipRanks
H.C. Wainwright raises Tourmaline Bio stock target to $50 - Investing.com India
Wedbush Lifts Price Target on Tourmaline Bio to $43 From $42, Keeps Outperform Rating - Marketscreener.com
Novo Nordisk (0QIU) Gets a Buy from UBS - The Globe and Mail
Tourmaline Bio’s 2024 Financial Results and Strategic Advances - TipRanks
Tourmaline Bio shares fall as Q4 loss widens - Investing.com
Tourmaline Bio shares fall as Q4 loss widens By Investing.com - Investing.com UK
TOURMALINE BIO Earnings Results: $TRML Reports Quarterly Earnings - Nasdaq
Tourmaline Bio, Inc. SEC 10-K Report - TradingView
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Tourmaline Bio's cash position to provide cash runway into second half of 2027 -March 13, 2025 at 07:39 am EDT - Marketscreener.com
Tourmaline Bio, Inc. Announces Over-Enrolled Phase 2 TRANQUILITY Trial and Strengthens Cardiovascular Scientific Advisory Board Amid Positive Financial Outlook - Nasdaq
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business - Bluefield Daily Telegraph
Tourmaline Bio Secures 2.5-Year Cash Runway with $294M, Accelerates Key Clinical Trials - StockTitan
Tourmaline Bio (TRML) Projected to Post Earnings on Tuesday - Defense World
Wedbush Forecasts Tourmaline Bio FY2024 Earnings - Defense World
Tourmaline Bio (NASDAQ:TRML) Research Coverage Started at Wedbush - Defense World
Rhumbline Advisers Has $722,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio rises as Wedbush initiates with Outperform - MSN
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - NewsBreak
Wedbush bullish on Tourmaline Bio, initiates with an Outperform - TipRanks
Wedbush Initiates Coverage on Tourmaline Bio With Outperform Rating, $42 Price Target - Marketscreener.com
Wedbush Initiates Tourmaline Bio at Outperform With $42 Price Target -March 06, 2025 at 07:22 am EST - Marketscreener.com
We Tested Over 25 Curling Irons. These 13 Are the Best - MarieClaire.com
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
Volatus Aerospace and Draganfly Expand Collaboration to Service High-Value Geospatial Power Utility Customers - The Manila Times
3 Reasons to Buy American Express Stock Like There's No Tomorrow - The Globe and Mail
When and Where to Catch Tourmaline Bio's Next Investor Presentation - StockTitan
Brokers Set Expectations for Tourmaline Bio FY2024 Earnings - MarketBeat
Truist maintains $74 target on Tourmaline Bio stock, reiterates buy By Investing.com - Investing.com UK
Lifesci Capital Predicts Tourmaline Bio FY2024 Earnings - Defense World
Financial Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) - Defense World
Lifesci Capital Initiates Coverage on Tourmaline Bio (NASDAQ:TRML) - Armenian Reporter
Tourmaline Bio (NASDAQ:TRML) Coverage Initiated by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Tourmaline Bio (TRML) with Outperform Recommendation - MSN
Talaris Therapeutics stock hits 52-week low at $12.06 By Investing.com - Investing.com Australia
Talaris Therapeutics stock hits 52-week low at $12.06 - Investing.com
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Vaxcyte (NASDAQ:PCVX) & Tourmaline Bio (NASDAQ:TRML) Financial Review - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $54.00 Average PT from Brokerages - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):